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Isolation and culture of primary hematopoietic cells
Patient PBMC obtained prior to alloSCT were stained with FITC-conjugated anti-CD14, PE-conjugated anti-CD3 and APC-conjugated anti-CD19 antibodies (BD Biosciences), and monocytes, T cells and B cells were isolated by flowcytometry based on expression of CD14, CD3 and CD19, respectively. In addition, PB and BM samples from patients with CML, AML, ALL, CLL and MM were stained with APC-conjugated anti-CD34, anti-CD33 or anti-CD19, and PE-conjugated anti-CD5 or anti-CD38 antibodies (BD Biosciences). CD34 + CML, CD33 + AML, CD19 + ALL, CD19 + CD5 + CLL and CD38 + MM cells were subsequently isolated by flowcytometry. Isolated CD34 + CML progenitor cells were modified into leukemic APC, 2 and isolated monocytes were cultured to immature and mature dendritic cells (DC) 3 as previously described.
Enzyme linked immunosorbent assay
Stimulator cells (3×10 4 cells/well) were co-incubated with CD8 + T-cell clones (5×10 3 cells/well) overnight at 37°C in Ubottom 96-well plates. Peptide pulsing was performed by incubating donor EBV-B cells (1×10 6 cell/mL) for 2 h with synthetic peptides in IMDM with 2% FBS. Peptide-pulsed donor EBV-B cells were washed twice and subsequently used as stimulator cells. Release of IFN-γ was measured in 50 μL culture supernatants by enzyme linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Sanquin, Burton upon Trent, UK).
Chromium release assay
Target cells were labeled for 1 h at 37°C with 100 μCi (3.7 MBq) Na2 51 CrO4 (Amersham, Uppsala, Sweden). After washing, target cells (1×10 3 cells/well) were incubated with CD8 + Tcell clones at different effector-to-target (E:T) ratios for 4 or 10 h. Release of 51 Cr was analyzed in 25 μL supernatants. The percentage of specific lysis was calculated with the following formula:
[experimental release (cpm) -spontaneous release (cpm)]/[maximal release (cpm) -spontaneous release (cpm)] x 100%.
Maximal release was induced by 1% Triton (Sigma-Aldrich).
Colony forming cell assay
BM samples were incubated with irradiated (20 Gy) CD8 + Tcell clones at E:T ratios of 3:1. After overnight pre-incubation, single cell suspensions were cultured at 2×10 4 target cells/mL in 30 mm culture dishes containing IMDM with methylcellulose supplemented with growth factors (GM-CSF, stem cell factor, IL-3, erythropoietin and other supplements; MethoCult, STEMCELL technologies SARL, Grenoble, France). As controls, single cell suspensions containing 2×10 4 target cells/mL and irradiated T cells at E:T ratios of 3:1 were seeded without pre-incubation. After 14 days of culture, numbers of colony forming units (CFU) for granulocyte/monocyte (CFU-GM) and erythroid lineages were scored.
Construction and screening of a plasmid cDNA expression library
A cDNA library was constructed as previously described. 4 Poly(A) + mRNA was isolated from patient EBV-B cells, and converted to cDNA using an oligo-d(T) primer. The cDNA was size-fractionated using column chromatography and ligated into pCR3.1 (Invitrogen, Breda, The Netherlands). Ligation products were transformed into E. Coli Top10 bacteria, and ampicillin resistant clones were divided into pools of approx. 50 different cDNA. Pools of cDNA were transfected into COS-7 cells stably expressing HLA-B*40:01. Transfection and screening of the cDNA library was performed using different mixtures of MiHA specific CD8 + T-cell clones.
Whole genome association scanning
WGAs were performed as previously described. 5 Briefly, a panel of 60 EBV-B cell lines stably expressing HLA-B*40:01 endogenously or after retroviral transduction (>20% marker gene expression) was tested for T-cell recognition in IFN-γ ELISA. For each T-cell clone, EBV-B cell lines were divided into MiHA positive and negative groups based on a threshold of 5-fold the background production of IFN-γ. All EBV-B cells included in the panel were genotyped for more than 1.1 million SNPs by Human 1M-duo arrays (Illumina, Inc., San Diego, CA, USA). WGAs analysis was performed by combining T-cell recognition and SNP genotyping data using Plink software (http://pngu.mgh.harvard.edu/purcell/plink/ version 1.03), and the significance of association between both patterns was calculated using Fisher's exact test.
Genotyping for single nucleotide polymorphisms
Genomic DNA was isolated by the Gentra Systems PureGene genomic isolation kit (Biocompare, San Francisco, CA, USA). SNP rs1049232 in the TRIP10 gene was analyzed using forward and reverse primers for amplification and two TaqMan MGB probes labeled with VIC and FAM dyes to detect the different alleles (Applied Biosystems, Foster City, CA, USA). Genotyping for SNP rs1049229 (TRIP10), rs13047599 (SON DNA binding protein), rs415895 (SWAP70) and rs1065674 (NUP133) was performed using allele-specific primers labeled with VIC and FAM dyes according to the manufacturer's instructions (KBioScience, Hoddesdon, UK).
Microarray gene expression analysis
Malignant cells were isolated from PB and BM samples from patients with CML, AML, ALL, CLL and MM by flowcytometry based on expression of CD34, CD33, CD19, CD19/CD5 and CD38, respectively. Non-malignant B cells, T cells and monocytes were isolated from PBMC based on expression of CD19, CD3 and CD14, respectively. Hematopoietic stem cells (HSC) were isolated from G-CSF mobilized PB based on expression of CD34. Non-hematopoietic cells included skinderived FB and KC, and PTEC cultured with and without IFN-γ (100 IU/mL). Total RNA was isolated using small and micro scale RNAqueous isolation kits (Ambion, Inc., Austin, TX, USA), and amplified using the TotalPrep RNA amplification kit (Ambion). After preparation using the whole-genome gene expression direct hybridization assay (Illumina), cRNA samples were dispensed onto Human HT-12 v3 Expression BeadChips (Illumina). Hybridization was performed in the Illumina hybridization oven for 17 h at 58°C. Microarray gene expression data were analyzed using Rosetta Resolver 7.2 software.
In vivo T-cell monitoring
PB samples were stained with a mixture of FITC-conjugated antibodies against CD4, CD14, CD19 and CD56 as well as a mixture of APC-and PE-conjugated tetramers for the HLA-B*40:01 restricted MiHA or a mixture of an APC-conjugated HA-2 tetramer and PE-conjugated HA-1 tetramer. For each tetramer, a minimum of 5×10 5 PBMC were stained. Tetramers were constructed as previously described 6 with minor modifications.
Online Supplementary Figure S2 . T-cell mediated lysis of primary leukemic blasts. CD8 + T-cell clones specific for LB-TRIP10-1EPC, LB-SON-1R, LB-SWAP70-1Q and LB-NUP133-1R were investigated for cytolytic activity against primary leukemic blasts in 10 h In vivo monitoring for MiHA specific T cells. Screening for MiHA specific T cells was performed for the patient with CML from whom the T-cell clones were isolated. PB samples pre-DLI and 6 and 7 weeks post-DLI were selected for in vivo Tcell monitoring. PBMC were stained with a mixture of FITC-conjugated anti-CD4, CD14, CD19 and CD56 antibodies and a mixture of PE-and APC-conjugated tetramers containing LB-SWAP70-1Q, LB-NUP133-1R, LB-SON-1R or LB-TRIP10-1EPC, or a mixture of PE-conjugated HA-1 and APC-conjugated HA-2 tetramers. Cells were gated for negative expression of CD4, CD14, CD19 and CD56, and mean fluorescence intensities are shown for PEand APC-conjugated tetramers. Percentages are shown of gated cells that are double positive for PE-and APC-conjugated LB-SWAP70-1Q, LB-NUP133-1R, and LB-SON-1R tetramers, single positive for PE-conjugated LB-TRIP10-1EPC and HA-1 tetramers, and single positive for the APC-conjugated HA-2 tetramer.
